The results demonstrated that genetic liability to type 2 diabetes was significantly associated with an elevated risk of 12 gastrointestinal conditions, including gastroesophageal reflux disease, gastric ulcer, acute gastritis, chronic gastritis, irritable bowel syndrome, diverticular disease, acute pancreatitis, cholelithiasis, cholelithiasis with cholecystitis, nonalcoholic fatty liver disease, liver cirrhosis, and ulcerative colitis [70]
GLP-1 receptor agonists mimic the GLP-1 hormone, which regulates blood sugar and appetite
This approval follows data from the STEP UP trial, which indicated that the gher dose led to a significant weight loss of 18.7% compared to 3.9% for placebo, with some participants achieving over 25% weight loss
The honest answer to the question of effectiveness is: the jury is still out, and we need to be extremely cautious